$52.40
7.47% yesterday
Nasdaq, Nov 15, 10:19 pm CET
ISIN
US88023B1035
Symbol
TEM

Tempus AI Stock price

$52.40
+5.77 12.37% 1M
+12.15 30.19% 6M
+12.15 30.19% YTD
+12.15 30.19% 1Y
+12.15 30.19% 3Y
+12.15 30.19% 5Y
+12.15 30.19% 10Y
Nasdaq, Closing price Fri, Nov 15 2024
-4.23 7.47%
ISIN
US88023B1035
Symbol
TEM

Key metrics

Market capitalization $8.25b
Enterprise Value $8.24b
P/B ratio (TTM) P/B ratio 151.48
Cash position $466.32m
Short interest 4.27%

Is Tempus AI a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,897 stocks worldwide.

Tempus AI Stock Analysis

Unlock Scores for Free

Analyst Opinions

8 Analysts have issued a Tempus AI forecast:

5x Buy
63%
3x Hold
38%

Analyst Opinions

8 Analysts have issued a Tempus AI forecast:

Buy
63%
Hold
38%

Financial data from Tempus AI

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
181 181
-
100%
- Direct Costs 78 78
-
43%
103 103
-
57%
- Selling and Administrative Expenses 89 89
-
49%
- Research and Development Expense 58 58
-
32%
-44 -44
-
-24%
- Depreciation and Amortization 9.44 9.44
-
5%
EBIT (Operating Income) EBIT -54 -54
-
-30%
Net Profit -76 -76
-
-42%

In millions USD.

Don't miss a Thing! We will send you all news about Tempus AI directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Tempus AI Stock News

Positive
Seeking Alpha
3 days ago
Tempus AI, Inc. founded in 2015, leverages AI for precision medicine, showing strong growth since its June 2024 listing, presenting a buying opportunity. The company boasts a vast clinical and molecular data library, advanced AI algorithms, and strategic partnerships with pharmaceutical giants like Merck and BioNTech. Despite profitability concerns and high cash burn, Tempus AI's revenue growth...
Neutral
Business Wire
5 days ago
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced publication of its study, “Actionable structural variant detection via RNA-NGS and DNA-NGS in patients with advanced non-small cell lung cancer,” in JAMA Network Open. Tempus recently conducted a retrospective study of more than...
Neutral
Seeking Alpha
7 days ago
Tempus AI, Inc. (NASDAQ:TEM ) Q3 2024 Earnings Conference Call November 4, 2024 4:30 PM ET Company Participants Liz Krutoholow – Investor Relations Eric Lefkofsky – Founder and Chief Executive Officer Jim Rogers – Chief Financial Officer Conference Call Participants Tejas Savant – Morgan Stanley Rachel Vatnsdal – JPMorgan Michael Ryskin – Bank of America Daniel Brennan – TD Cowen Ryan MacDonald...
More Tempus AI News

Company Profile

Tempus AI, Inc. is a healthcare technology company, which engages in bringing artificial intelligence and machine learning to healthcare. It focuses on building platforms for oncology, neuropsychiatry, cardiology, infectious disease, and radiology. The company was founded by Eric Paul Lefkofsky in August 2015 and is headquartered in Chicago, IL.

Head office United States
CEO Eric Lefkofsky
Website www.tempus.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today